Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 14 PAGES: 84

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2012, provides an overview of the Leishmaniasis (Kala-Azar) therapeutic pipeline. This report provides information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar). 'Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									 Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1831IDB
                                                                                             Publication Date: March 2012




Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012                                        GMDHC1831IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 7
    List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
    Global Markets Direct Report Coverage ........................................................................................................................................ 8
Leishmaniasis (Kala-Azar) Overview .................................................................................................................................................. 9
Therapeutics Development............................................................................................................................................................... 10
    An Overview of Pipeline Products for Leishmaniasis (Kala-Azar)................................................................................................ 10
Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies .................................................................................. 12
Leishmaniasis (Kala-Azar) Therapeutics under Investigation by Universities/Institutes ................................................................... 13
Late Stage Products ......................................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Mid Clinical Stage Products.............................................................................................................................................................. 16
    Comparative Analysis .................................................................................................................................................................. 16
Early Clinical Stage Products ........................................................................................................................................................... 17
    Comparative Analysis .................................................................................................................................................................. 17
Pre-Clinical Stage Products.............................................................................................................................................................. 18
    Comparative Analysis .................................................................................................................................................................. 18
Leishmaniasis (Kala-Azar) Therapeutics – Products under Development by Companies ................................................................ 19
Leishmaniasis (Kala-Azar) Therapeutics – Products under Investigation by Universities/Institutes ................................................. 20
Companies Involved in Leishmaniasis (Kala-Azar) Therapeutics Development ............................................................................... 22
    iCo Therapeutics Inc.................................................................................................................................................................... 22
    MOLOGEN AG ............................................................................................................................................................................ 23
    Dafra Pharma International Ltd.................................................................................................................................................... 24
    aRigen Pharmaceuticals, Inc. ...................................................................................................................................................... 25
Leishmaniasis (Kala-Azar) – Therapeutics Assessment .................................................................................................................. 26
    Assessment by Monotherapy Products ....................................................................................................................................... 26
    Assessment by Combination Products ........................................................................................................................................ 27
    Assessment by Route of Administration ...................................................................................................................................... 28
    Assessment by Molecule Type .................................................................................................................................................... 30
Drug Profiles..................................................................................................................................................................................... 32
    Miltefosine For Leishmaniasis - Drug Profile ............................................................................................................................... 32
         Product Description................................................................................................................................................................. 32
         Mechanism of Action ............................................................................................................................................................... 32
         R&D Progress ......................................................................................................................................................................... 32
    Miltefosine - Drug Profile ............................................................................................................................................................. 33
         Product Description................................................................................................................................................................. 33
         Mechanism of Action ............................................................................................................................................................... 33
         R&D Progress ......................................................................................................................................................................... 33
    Zitromax - Drug Profile ................................................................................................................................................................ 34
         Product Description................................................................................................................................................................. 34
         Mechanism of Action ............................................................................................................................................................... 34



Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012                                                                                            GMDHC1831IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012




        R&D Progress ......................................................................................................................................................................... 34
    Ambisome - Drug Profile ............................................................................................................................................................. 35
        Product Description................................................................................................................................................................. 35
        Mechanism of Action ............................................................................................................................................................... 35
        R&D Progress ......................................................................................................................................................................... 35
    Miltefosine + Liposomal Amphotericin B - Drug Profile ................................................................................................................ 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    Ambisome + Miltefosine - Drug Profile ........................................................................................................................................ 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    Ambisome + Paromomycin - Drug Profile.................................................................................................................................... 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    Miltefosine + Paromomycin - Drug Profile ................................................................................................................................... 39
        Product Description................................................................................................................................................................. 39
        Mechanism of Action ............................................................................................................................................................... 39
        R&D Progress ......................................................................................................................................................................... 39
    Amphotericin B Deoxycholate - Drug Profile ............................................................................................................................... 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    Liposomal Amphotericin B + Miltefosine - Drug Profile ................................................................................................................ 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    Liposomal Amphotericin B + Paromomycin Sulfate - Drug Profile ............................................................................................... 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    Paromomycin Sulfate + Miltefosine - Drug Profile ....................................................................................................................... 45
        Product Description................................................................................................................................................................. 45
        Mechanism of Action ............................................................................................................................................................... 45
        R&D Progress ......................................................................................................................................................................... 45
    Miltefosine + Paromomycin Sulfate - Drug Profile ....................................................................................................................... 47
        Product Description................................................................................................................................................................. 47
        Mechanism of Action ............................................................................................................................................................... 47
        R&D Progress ......................................................................................................................................................................... 47
    Leish-111f + MPL-SE - Drug Profile ............................................................................................................................................ 48
        Product Description................................................................................................................................................................. 48
        Mechanism of Action ............................................................................................................................................................... 48


Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012                                                                                        GMDHC1831IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(3)
Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012




        R&D Progress ......................................................................................................................................................................... 48
    AmBisome + Paromomycin Sulfate - Drug Profile ....................................................................................................................... 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    Pentostam - Drug Profile ............................................................................................................................................................. 51
        Product Description................................................................................................................................................................. 51
        Mechanism of Action ............................................................................................................................................................... 51
        R&D Progress ......................................................................................................................................................................... 51
    Paromomycin - Drug Profile......................................................................................................................................................... 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    Paromomycin + Gentamicin - Drug Profile .................................................................................................................................. 53
        Product Description................................................................................................................................................................. 53
        Mechanism of Action ............................................................................................................................................................... 53
        R&D Progress ......................................................................................................................................................................... 53
    Miltefosine - Drug Profile ............................................................................................................................................................. 54
        Product Description................................................................................................................................................................. 54
        Mechanism of Action .................................................................................................
								
To top